The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1046
February 12, 1999
View Complete Issue         Table of Contents 2019 
Mometasone Furoate Nasal Spray for Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Mometasone Furoate Nasal Spray for Allergic Rhinitis
February 12, 1999 (Issue: 1046)
An intranasal spray formulation of the topical corticosteroid mometasone furoate, marketed for treatment of seasonal and perennial allergic rhinitis, has been advertised on television directly to the public.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Mometasone Furoate Nasal Spray for Allergic Rhinitis
Article code: 1046b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.